Curated News
By: NewsRamp Editorial Staff
June 12, 2025
Nutriband's AVERSA Fentanyl Patch Leads Abuse-Deterrent Innovation
TLDR
- Nutriband's Q1 financial report shows a 63% revenue increase, positioning it as a leader in abuse-deterrent drug delivery with its AVERSA(TM) Fentanyl patch.
- Nutriband advances its AVERSA(TM) Fentanyl patch development, aiming to create the first abuse-deterrent opioid patch, with a 63% revenue growth in Q1 2025.
- Nutriband's development of the AVERSA(TM) Fentanyl patch could significantly reduce opioid abuse, making a safer tomorrow for patients worldwide.
- Discover how Nutriband's innovative AVERSA(TM) Fentanyl patch could revolutionize pain management by deterring abuse, with a 63% revenue jump in Q1.
Impact - Why it Matters
Nutriband's development of the AVERSA(TM) Fentanyl patch represents a critical advancement in addressing the opioid crisis by offering a safer, abuse-deterrent option. This innovation could significantly reduce the potential for misuse of fentanyl patches, a pressing public health issue. The company's financial growth and strategic initiatives highlight its potential to make a meaningful impact in the pharmaceutical industry and beyond.
Summary
Nutriband Inc. (NASDAQ: NTRB) is making significant strides in the pharmaceutical industry with its innovative AVERSA(TM) Fentanyl patch, poised to be the world's first abuse-deterrent opioid patch. The company's recent Q1 financial report highlights a 63% year-over-year revenue increase to $667,000, fueled by its subsidiary Pocono Pharma's expansion in kinesiology tape manufacturing. Nutriband's strategic partnerships and expanded intellectual property portfolio underscore its commitment to leading the development of safer transdermal therapies. For more details, visit Read More>>.
BioMedWire, a specialized communications platform, provides comprehensive coverage on Nutriband's advancements and other developments in the Biotechnology and Life Sciences sectors. It offers a range of services to enhance corporate communications and ensure maximum impact for its clients. Discover more at BioMedWire.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband's AVERSA Fentanyl Patch Leads Abuse-Deterrent Innovation
